Categories: Health

OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025

 | Source: OPKO Health, Inc.

MIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on Thursday, February 27, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on February 27th beginning at 4:30 p.m. Eastern time.

CONFERENCE CALL & WEBCAST INFORMATION

OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed at OPKO’s Investor Relations page and here.

A telephone replay will be available until March 6, 2025, by dialing 877-344-7529 (U.S.) or 412-317-0088 (International) and providing the passcode 8087517. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here.

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.

Contacts:

Alliance Advisors IR
Yvonne Briggs, 310-691-7100
ybriggs@allianceadvisors.com
or
Bruce Voss, 310-691-7100
bvoss@allianceadvisors.com

GlobeNews Wire

Recent Posts

Quantinuum Selected by DARPA to Advance to First Stage of Quantum Benchmarking Initiative

With the industry's most advanced quantum systems and proven ability to scale, Quantinuum is on…

1 hour ago

Best SARMs For Cutting, Bulking & Muscle Growth 2025: Top Fat Loss Sarms Stack For Sale On The Market – CrazyBulk

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Welcome to the world of SARMs, the…

2 hours ago

HealthRecon Connect Achieves ISO 22301:2019 Certification for Business Continuity Management

DALLAS, April 03, 2025 (GLOBE NEWSWIRE) -- HealthRecon Connect is proud to announce that it…

2 hours ago

EssilorLuxottica and Roger Federer Extend Exclusive Global Eyewear Collaboration Between the RF Brand and Oliver Peoples

EssilorLuxottica and Roger Federer Extend Exclusive Global Eyewear Collaboration Between the RF Brand and Oliver…

2 hours ago

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025 OSE-CYTOMASK®, a new…

2 hours ago

Valneva SE Shareholding Declaration – March 2025

VALNEVA Declaration of shares and voting rights March 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6…

2 hours ago